Epidermal Growth Factor Receptor (egfr) Inhibitors - Cancer Science

Relevant Publications

Tanreqing injection inhibits stemness and enhances sensitivity of non-small cell lung cancer models to gefitinib through ROS/STAT3 signaling pathway.

Issue Release: 2024

A Visual Analysis of the Research Dynamics in Resistance to EGFR Inhibitors for NSCLC.

Issue Release: 2024

Ononin inhibits triple-negative breast cancer lung metastasis by targeting the EGFR-mediated PI3K/Akt/mTOR pathway.

Issue Release: 2024

Current perspectives of KRAS in non-small cell lung cancer.

Issue Release: 2024

Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.

Issue Release: 2024

Targeted analysis of Ubiquitin-Specific Peptidase (USP8) in a population of Iranian people with Cushing\'s disease and a systematic review of the literature.

Issue Release: 2024

Cancer mutational signatures identification in clinical assays using neural embedding-based representations.

Issue Release: 2024

Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control.

Issue Release: 2024

Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive -mutant Non-small Cell Carcinoma.

Issue Release: 2024

Drug-Induced Reorganisation of Lipid Metabolism Limits the Therapeutic Efficacy of Ponatinib in Glioma Stem Cells.

Issue Release: 2024

Strategies for Enhancing Non-small Cell Lung Cancer Treatment: Integrating Chinese Herbal Medicines with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Therapy.

Issue Release: 2024

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Issue Release: 2024

Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy.

Issue Release: 2024

Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents.

Issue Release: 2024

[Progress and Discussion of Perioperative Targeted Therapy in Patients  with EGFR-mutated Resectable Non-small Cell Lung Cancer].

Issue Release: 2024

Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.

Issue Release: 2024

Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired 19Del/T790M/-C797S mutation resistance.

Issue Release: 2024

Nanoenabled intracellular zinc bursting for efficacious reversal of gefitinib resistance in lung cancer.

Issue Release: 2024

PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.

Issue Release: 2024

Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents.

Issue Release: 2024

What role do biomarkers play in cancer treatment?

How Do Blister Packs Benefit Cancer Patients?

How to Prepare for Bone Marrow Aspiration?

What are the Benefits of Telemedicine in Cancer Care?

Which Types of Cancer Are Most Commonly Associated with Dysphagia?

How do Keratins Affect Tumor Behavior?

Which Cancers are Associated with MSI-H?

What are the Challenges in Using Natural Compounds for Cancer Treatment?

How is Processed Meat Linked to Cancer?

Why is Tumor Location Important in Cancer?

Epidermal Growth Factor Receptor (egfr) Inhibitors - Cancer Science

Relevant Publications

Partnered Content Networks

Relevant Topics